Assessment of PARP1 mRNA expression as prognostic of aggressive pathology and adverse outcomes, and as predictor of response to PARP inhibition in castration-sensitive prostate cancer. Association of ...
IGHV status significantly influences CLL prognosis, with mutated IGHV linked to longer survival and unmutated IGHV to shorter progression-free survival. NGS enhances IGHV analysis by overcoming Sanger ...
Nearly half of people diagnosed with advanced cancer over a recent 5-year period did not undergo next-generation sequencing, according to results of a retrospective cohort study.Rates improved over ...
Azeliragon, a RAGE inhibitor, in combination with temozolomide and radiotherapy in patients with newly diagnosed glioblastoma: Preliminary results of phase Ib/II CAN-201 NDG trial. Immunohistochemical ...
The webinar series titled "The Basics of Next Generation Sequencing and its Application in Precision Oncology" aims to provide a comprehensive understanding of the fundamentals and practical ...
Oxford Gene Technology has announced the launch of its newly updated NGS SureSeq™ CLL + CNV V3 Panel. This new panel was designed to offer users more comprehensive variant detection to improve ...
New innovations improve microbial identification, outbreak tracking, and NGS workflows, enhancing diagnostic speed, accuracy, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results